Processa Pharmaceuticals, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories (Details) (Parenthetical) - USD ($)	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Interim Period, Costs Not Allocable [Line Items]
Personnel costs include employee stock-based compensation expense	$ 857,550	$ 629,514
Research and Development Personnel Costs [Member]
Interim Period, Costs Not Allocable [Line Items]
Personnel costs include employee stock-based compensation expense	192,630	169,414
General and Administrative Personnel Costs [Member]
Interim Period, Costs Not Allocable [Line Items]
Personnel costs include employee stock-based compensation expense	$ 508,644	$ 186,925